Houston, Texas (November 7, 2014) – Today, The US Oncology Network, one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care, presented Bristol-Myers Squibb (BMS) with the inaugural LEAD Award during The Network’s Joint Fall Pharmacy & Therapeutics (P&T) and Annual Radiation & Imaging Meeting in Dallas.
The LEAD Award was created by The US Oncology Network to honor life sciences companies for Leadership in Education And Clinical Development. Bristol-Myers Squibb is the first recipient of this award. Through the discovery, development and commercialization of immuno-oncology agents, BMS has set an example of commitment to research and clinical education—leveraging the broad capabilities of The US Oncology Network to bring these innovative medicines to patients.
“Bristol-Myers Squibb has consistently demonstrated its commitment to innovation, science and high-quality cancer care in the development of the immuno-oncology therapeutic class,” said Barry D. Brooks, MD, oncologist and partner with Texas Oncology, and Chairman of The US Oncology Network Pharmacy & Therapeutics Committee. “We are proud to recognize Bristol-Myers Squibb for its outstanding contributions to the advancement of cancer care. Thousands of patients will benefit from this exciting class of drugs.”
The US Oncology Network is dedicated to improving the quality and delivery of cancer care. The Network participates in clinical trials through US Oncology Research (USOR), a leader in bringing innovative therapeutic options to patients in local communities, where they live and work. USOR has played a role in the development of 50 FDA-approved cancer therapies—nearly one-third of all oncology therapies used today.
“The vast majority of cancer patients in the U.S. receive their care in a community setting,” said Joseph Leveque, MD, Vice President, U.S. Medical - Oncology, Bristol-Myers Squibb. “Working with The US Oncology Network to develop and execute applied research and clinical studies, education programs, and policy centered on the imperative of improving cancer survivorship, is critical for delivering new therapies to cancer patients with unmet needs. We are proud to work together with this Network of dedicated physicians to help advance both the science and the art of immuno-oncology.”
US Oncology Research manages approximately 225 clinical trials at any given time for patients with all types of cancer. For more information on The US Oncology Network and US Oncology Research, visit www.usoncology.com.
About The US Oncology Network
The US Oncology Network is one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.
About US Oncology Research
Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research supports a large network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves 66 research sites and 194 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 58,000 patients in nearly 1,300 trials since inception in 1992 and have played a role in pivotal trials for 50 FDA-approved cancer therapies. USOR is able to work quickly to activate clinical trials across the nation, often times delivering trials to the first patient in the world or USA. Leveraging technology, a common electronic health record and with scale across the USA, USOR is able to offer clinical trials with more options for patients with cancer, in their community, near home. For more information call (800) 482-6700 or visit www.usoncology.com.